Key facts
- It has raised $54.8M; the latest was Later Stage VC ($28.9M) in Mar 2026.
- Notable investors include Oriental Fortune Capital, Zhejiang Silicon Paradise Asset Management Group, Liyuan Venture Capital, Shaoxing Shangyu Guokong Shunyun Private Equity Fund Management, Shulan Junjie Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for MHDC Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for MHDC Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MHDC Pharmaceutical
Developer of biopharmaceutical formulation intended for biopharmaceutical enterprises. The company develops novel biopharmaceutical formulations and conducts industrial-scale production, thereby enabling users to obtain reliable formulation pathways and compliant manufacturing structures.
- Sector
- Healthcare
- HQ
- Shaoxing, China
- Founded
- 2011
- Employees
- 60
- Website
- mhdcpharma.com/
- Ownership
- Privately Held (backing)
MHDC Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MHDC Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MHDC Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.